138 related articles for article (PubMed ID: 23013779)
1. The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression.
Mocroft A; Bannister WP; Kirk O; Kowalska JD; Reiss P; D'Arminio-Monforte A; Gatell J; Fisher M; Trocha H; Rakhmanova A; Lundgren JD;
Antivir Ther; 2012; 17(7):1291-300. PubMed ID: 23013779
[TBL] [Abstract][Full Text] [Related]
2. Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata.
Reekie J; Gatell JM; Yust I; Bakowska E; Rakhmanova A; Losso M; Krasnov M; Francioli P; Kowalska JD; Mocroft A;
AIDS; 2011 Nov; 25(18):2259-68. PubMed ID: 21918422
[TBL] [Abstract][Full Text] [Related]
3. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
[TBL] [Abstract][Full Text] [Related]
4. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
[TBL] [Abstract][Full Text] [Related]
5. Maintaining antiretroviral therapy reduces the risk of AIDS-defining events in patients with uncontrolled viral replication and profound immunodeficiency.
Kousignian I; Abgrall S; Grabar S; Mahamat A; Teicher E; Rouveix E; Costagliola D;
Clin Infect Dis; 2008 Jan; 46(2):296-304. PubMed ID: 18171266
[TBL] [Abstract][Full Text] [Related]
6. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
7. Risk of AIDS and death at given HIV-RNA and CD4 cell count, in relation to specific antiretroviral drugs in the regimen.
Olsen CH; Gatell J; Ledergerber B; Katlama C; Friis-Møller N; Weber J; Horban A; Staszewski S; Lundgren JD; Phillips AN;
AIDS; 2005 Feb; 19(3):319-30. PubMed ID: 15718843
[TBL] [Abstract][Full Text] [Related]
8. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
[TBL] [Abstract][Full Text] [Related]
9. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment.
Zhang S; van Sighem A; Gras L; Reiss P; Smit C; Kroon F; Jurriaans S; Prins J; Lange J; de Wolf F
Antivir Ther; 2010; 15(4):555-62. PubMed ID: 20587848
[TBL] [Abstract][Full Text] [Related]
11. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Bannister WP; Ruiz L; Loveday C; Vella S; Zilmer K; Kjaer J; Knysz B; Phillips AN; Mocroft A;
Antivir Ther; 2006; 11(6):707-15. PubMed ID: 17310815
[TBL] [Abstract][Full Text] [Related]
13. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
[TBL] [Abstract][Full Text] [Related]
14. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Lampe FC; Gatell JM; Staszewski S; Johnson MA; Pradier C; Gill MJ; de Lazzari E; Dauer B; Youle M; Fontas E; Krentz HB; Phillips AN
Arch Intern Med; 2006 Mar; 166(5):521-8. PubMed ID: 16534038
[TBL] [Abstract][Full Text] [Related]
15. Effect of maintaining highly active antiretroviral therapy on AIDS events among patients with late-stage HIV infection and inadequate response to therapy.
Gandhi T; Wei W; Amin K; Kazanjian P
Clin Infect Dis; 2006 Mar; 42(6):878-84. PubMed ID: 16477568
[TBL] [Abstract][Full Text] [Related]
16. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study.
Boillat-Blanco N; Darling KE; Schoni-Affolter F; Vuichard D; Rougemont M; Fulchini R; Bernasconi E; Aouri M; Clerc O; Furrer H; Günthard HF; Cavassini M;
Antivir Ther; 2015; 20(2):165-75. PubMed ID: 24964403
[TBL] [Abstract][Full Text] [Related]
17. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
18. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
19. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
20. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]